SCHEMBL4111012

SCHEMBL4111012

I/C=C/c1ccc(OCCN2CCOCC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
HPGD P15428 1/20 0.57
LTA4H P09960 2/20 0.57
GAA P10253 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 2/20 0.55
MAPK1 P28482 2/20 0.55
CYP1A2 P05177 1/20 0.55
CHRM2 P08172 1/20 0.55
CHRM1 P11229 1/20 0.55
HTR2A P28223 1/20 0.55
SCN1A P35498 1/20 0.55
HTR2B P41595 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4111014 1.00 NPC1 (0.58) NPC1RAB9AHPGDLTA4HGAA
SCHEMBL8508892 0.86 ALDH1A1 (0.58) NPC1RAB9AHPGDLTA4HGAA
SCHEMBL13460609 0.86 ALDH1A1 (0.58) NPC1RAB9AHPGDLTA4HGAA
SCHEMBL7487343 0.84 KEAP1 (0.61) NPC1RAB9AHPGDLTA4HGAA
SCHEMBL17061257 0.84 KEAP1 (0.61) NPC1RAB9AHPGDLTA4HGAA
SCHEMBL7487334 0.84 KEAP1 (0.61) NPC1RAB9AHPGDLTA4HGAA
SCHEMBL16485615 0.84 KEAP1 (0.61) NPC1RAB9AHPGDLTA4HGAA
SCHEMBL15648875 0.83 ALDH1A1 (0.59) NPC1RAB9AHPGDLTA4HGAA
SCHEMBL15648881 0.83 ALDH1A1 (0.59) NPC1RAB9AHPGDLTA4HGAA
Hydrochloric Acid SCHEMBL3424525 0.83 KEAP1 (0.63) NPC1RAB9AHPGDLTA4HGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090169558-A1 BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 NOVARTIS AG 2009-07-02 US disclosed
US-20090169558-A1 BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 NOVARTIS AG 2009-07-02 US disclosed
US-20090169558-A1 BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 NOVARTIS AG 2009-07-02 US disclosed
EP-1934223-A1 BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 Novartis Pharma AG (CH) 2008-06-25 EP disclosed
WO-2007039285-A1 BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 NOVARTIS AG (CH) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169558-A1 BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 MAP4K2, MAPKAPK2, MAP3K2 NPC1 3440/4885RAB9A 1133/4885HPGD 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.